middle.news
Nyrada Clears Ethics Hurdle to Launch Phase IIa Heart Attack Trial
11:33am on Thursday 8th of January, 2026 AEDT
•
Healthcare
Read Story
Nyrada Clears Ethics Hurdle to Launch Phase IIa Heart Attack Trial
11:33am on Thursday 8th of January, 2026 AEDT
Key Points
Human Research Ethics Committee approval granted for Phase IIa trial
Trial to assess safety and preliminary efficacy of Xolatryp in heart attack patients
Approximately 200 patients to be enrolled in a randomized, placebo-controlled study
Patient recruitment expected to begin March 2026 at up to 10 Australian hospitals
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NYRADA (ASX:NYR)
OPEN ARTICLE